CXCR2 and pancreatic ductal adenocarcinoma: Interestingly, other reports on a mouse model of pancreatic ductal adenocarcinoma demonstrated that the treatment with the CXCR2 inhibitor caused an improved response to chemotherapy with 5-Fluoruracil associated with a decrease in PMN-MDSC and an increase in CD8+ T cells [52] or the protection from liver metastasis linked to an increase in CD3+ T cells [53].